While MiNK Therapeutics Inc has underperformed by -2.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INKT rose by 184.12%, with highs and lows ranging from $76.00 to $4.56, whereas the simple moving average jumped by 132.09% in the last 200 days.
On July 14, 2025, William Blair Downgraded MiNK Therapeutics Inc (NASDAQ: INKT) to Mkt Perform.
Analysis of MiNK Therapeutics Inc (INKT)
In order to gain a clear picture of MiNK Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 0.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 939.67K can be a very valuable indicator of volatility for INKT stock. On a monthly basis, the volatility of the stock is set at 25.72%, whereas on a weekly basis, it is put at 25.47%, with a loss of -51.24% over the past seven days. Furthermore, long-term investors anticipate a median target price of $39.00, showing growth from the present price of $19.8, which can serve as yet another indication of whether INKT is worth investing in or should be passed over.
How Do You Analyze MiNK Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 75.14%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 1.58% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
INKT shares are owned by institutional investors to the tune of 1.58% at present.
